Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01207635

Enrollment

Registered

2010-09-23

Start date

2002-11-30

Completion date

2006-01-31

Last updated

2012-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Cancer, Arimidex

Brief summary

The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients. Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.

Interventions

PROCEDUREDuctal Lavage Fluid Collection

Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Patient must have a history of breast cancer. * Patient must be scheduled to receive standard treatment with Arimidex for adjuvant hormonal management. * Patient must be willing to undergo a duct lavage. * Patient must sign an Informed Consent.

Exclusion criteria

* None.

Design outcomes

Primary

Measure	Time frame	Description
Number of Patients with Antiproliferative Effects of Arimidex	Study duration 4 years	Biomarker modulation study on effects of Armimidex in ductal lavage fluid from evaluable epithelial cells specimen.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026